L’empagliflozine (Jardiance ®), un nouvel hypoglycémiant dans le traitement du diabète de type 2, diminue aussi le risque cardiovasculaire : analyse d’une étude princeps
(2015) Louvain médical — Vol. 134, n° 8, p. 403-408 (2015)
Files
2015_Buysschaert_LM_1348_403-408.pdf
Restricted Access - Adobe PDF
- 272.95 KB
Details
- Authors
- Abstract
- (en) [Empagliflozin (Jardiance ®), a novel hypoglycemic agent in the treatment of type 2 diabetes, also reduces cardiovascular risk: analysis of a princeps study] Cardiovascular morbidity and mortality are increased in Type 2 diabetes patients, when compared with a non-diabetic population. Prevention of macrovascular disease in diabetic patients is primarily based on glycemic control and adequate therapy of conventional risk factors. Recently, empagloflozin (Jardiance®), a treatment of chronic hyperglycemia has been shown to be associated with improved cardiovascular outcomes. In the EMPA-REG OUTCOME study, type 2 diabetes patients at high risk of developing cardiovascular events displayed a lower rate of the primary composite cardiovascular outcome (death from cardiovascular causes, non-fatal myocardial infarction or non-fatal cerebrovascular accident) (HR: 0.86 [95.02% CI:0.74-0.89]), as well as a reduction in cardiovascular death (-38%, p<0.001), death from any cause (-32%; p<0.001), and hospitalization for heart failure (-35%, p=0.002), when empagloflozin was added to prior antihyperglycemic treatment, as compared to patients receiving placebo instead. At inclusion, these patients were already adequately treated for conventional cardiovascular risk factors. Major side-effects were genital infections. In view of this data, empagliflozin should be considered a privileged agent in the therapeutic approach of Type 2 diabetic patients at high risk for cardiovascular events.
- Affiliations
Citations
Buysschaert, M. (2015). L’empagliflozine (Jardiance ®), un nouvel hypoglycémiant dans le traitement du diabète de type 2, diminue aussi le risque cardiovasculaire : analyse d’une étude princeps. Louvain médical, 134(8), 403-408. https://hdl.handle.net/2078.5/79164 (Original work published 2015)